Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 13/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 8/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 8/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 2/20 | 1.00 |
| ▸ | CHRNG | P07510 | 2/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 2/20 | 1.00 |
| ▸ | CHRND | Q07001 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4408107 | 0.98 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL5767352 | 0.89 | CHRNB2 (0.81) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Hydrochloric Acid SCHEMBL6392186 | 0.88 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL6908685 | 0.82 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL16905570 | 0.79 | CHRNA1 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL16905466 | 0.78 | CHRNA1 (0.64) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL3445492 | 0.78 | CHRNA1 (0.64) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL5996036 | 0.78 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL5686052 | 0.78 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Hydrochloric Acid SCHEMBL6824751 | 0.76 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1619192-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2009-12-30 | — | — | EP | claimed |
| US-7205300-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2007-04-17 | — | — | US | claimed |
| US-7144882-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2006-12-05 | — | — | US | claimed |
| EP-1699488-A2 | THERAPEUTIC COMBINATION FOR COGNITION ENHANCEMENT AND PSYCHOTIC DISORDERS | Pfizer Products Incorporated (US) | 2006-09-13 | — | — | EP | claimed |
| EP-1259489-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2006-06-07 | — | — | EP | claimed |
| EP-1658059-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658058-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1626738-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | claimed |
| EP-1619192-A2 | Aryl fused azapolycyclic compounds | Pfizer Products Inc. (US) | 2006-01-25 | — | — | EP | claimed |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC | 2005-11-10 | — | — | US | claimed |
| US-20030008892-A1 | Pharmaceutical composition and method of modulating cholinergic function in a mammal | PFIZER INC. | 2003-01-09 | — | — | US | claimed |
| US-20020193360-A1 | Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders | PFIZER INC. | 2002-12-19 | — | — | US | claimed |
| WO-2002069948-A1 | USE OF GABAA INVERSE AGONISTS IN COMBINATION WITH NICOTINE RECEPTOR PARTIAL AGONISTS, ESTROGEN, SELECTIVE ESTROGEN MODULATORS, OR VITAMIN E FOR THE TREATMENT OF COGNITIVE DISORDERS | PFIZER PRODUCTS INC. (GB) | 2002-09-12 | — | — | WO | claimed |
| US-20020016334-A1 | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) | COE JOTHAM WADSWORTH (US) | 2002-02-07 | — | — | US | claimed |
| EP-1177798-A2 | A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder(ADHD) comprising a nicotine receptor partial agonist and anti-ADHD agent | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| US-20020010192-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC. | 2002-01-24 | — | — | US | claimed |
| EP-1159970-A2 | A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss, comprising a nicotine receptor partial agonist and an anti-obesity agent | Pfizer Products Inc. (US) | 2001-12-05 | — | — | EP | claimed |
| US-20010036943-A1 | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines | PFIZER PRODUCTS INC. | 2001-11-01 | — | — | US | claimed |
| US-20010036949-A1 | Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal | PFIZER PRODUCTS INC. | 2001-11-01 | — | — | US | claimed |
| EP-1078637-A2 | Composition for the treatment and prevention of nicotine addiction containing a nicotine receptor agonist and an anti-depressant or anti-anxiety drug | Pfizer Products Inc. (US) | 2001-02-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016334-A1 | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) | CHRNB4, CHRNA10, CHRNA7 | CHRNB2 7/4885CHRNA4 11/4885CHRNB4 1/4885 |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | CHRNA5, CHRNA1, CHRNA2 | CHRNB2 19/4885CHRNA4 4/4885CHRNB4 20/4885 |
| US-20020193360-A1 | Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders | CHRNE, CHRNA10, GABRE | CHRNB2 15/4885CHRNA4 10/4885CHRNB4 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.